Literature DB >> 3403993

Predictors of short-term prognosis in patients with pulmonary tuberculosis.

P F Barnes1, J M Leedom, L S Chan, S F Wong, J Shah, L A Vachon, G D Overturf, R L Modlin.   

Abstract

We evaluated 191 consecutive adults with pulmonary tuberculosis in order to develop methods to determine which patients should be initially hospitalized. Using stepwise discriminant analysis, we found the six factors that were most strongly associated with an unfavorable short-term outcome (respiratory failure or death): lymphopenia, advanced age, concomitant smear-positive extrapulmonary tuberculosis, alcoholism, a high percentage of neutrophils on the differential white blood cell count, and lack of radiographic evidence of cavitation. We derived a scoring system incorporating these variables and separated patients into high- and low-risk groups. The system was prospectively validated by applying it to a separate group of 179 patients. Lymphocyte-transformation tests in 32 patients revealed an association between clinical markers of poor prognosis and minimal lymphocyte proliferation to a heat-killed strain of Mycobacterium tuberculosis.

Entities:  

Mesh:

Year:  1988        PMID: 3403993     DOI: 10.1093/infdis/158.2.366

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  26 in total

Review 1.  Current medical treatment for tuberculosis.

Authors:  Edward D Chan; Michael D Iseman
Journal:  BMJ       Date:  2002-11-30

2.  Clinical value of the measurement of Mycobacterium tuberculosis specific antibody in pulmonary tuberculosis.

Authors:  G H Bothamley; R Rudd; F Festenstein; J Ivanyi
Journal:  Thorax       Date:  1992-04       Impact factor: 9.139

3.  Macrophage migration inhibitory factor (MIF) is a critical mediator of the innate immune response to Mycobacterium tuberculosis.

Authors:  Rituparna Das; Mi-Sun Koo; Bae Hoon Kim; Shevin T Jacob; Selvakumar Subbian; Jie Yao; Lin Leng; Rebecca Levy; Charles Murchison; William J Burman; Christopher C Moore; W Michael Scheld; John R David; Gilla Kaplan; John D MacMicking; Richard Bucala
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-23       Impact factor: 11.205

Review 4.  The Goldilocks model of immune symbiosis with Mycobacteria and Candida colonizers.

Authors:  Richard T Robinson; Anna R Huppler
Journal:  Cytokine       Date:  2017-05-29       Impact factor: 3.861

Review 5.  Tuberculosis and HIV disease: two decades of a dual epidemic.

Authors:  Muktar H Aliyu; Hamisu M Salihu
Journal:  Wien Klin Wochenschr       Date:  2003-10-31       Impact factor: 1.704

Review 6.  Impact of Childhood Malnutrition on Host Defense and Infection.

Authors:  Marwa K Ibrahim; Mara Zambruni; Christopher L Melby; Peter C Melby
Journal:  Clin Microbiol Rev       Date:  2017-10       Impact factor: 26.132

Review 7.  Sex differences in tuberculosis.

Authors:  David Hertz; Bianca Schneider
Journal:  Semin Immunopathol       Date:  2018-10-25       Impact factor: 9.623

Review 8.  The need for epidemic intelligence.

Authors:  A B Bloch; I M Onorato; W W Ihle; J L Hadler; C H Hayden; D E Snider
Journal:  Public Health Rep       Date:  1996 Jan-Feb       Impact factor: 2.792

9.  Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment.

Authors:  Anna K Coussens; Robert J Wilkinson; Yasmeen Hanifa; Vladyslav Nikolayevskyy; Paul T Elkington; Kamrul Islam; Peter M Timms; Timothy R Venton; Graham H Bothamley; Geoffrey E Packe; Mathina Darmalingam; Robert N Davidson; Heather J Milburn; Lucy V Baker; Richard D Barker; Charles A Mein; Leena Bhaw-Rosun; Rosamond Nuamah; Douglas B Young; Francis A Drobniewski; Christopher J Griffiths; Adrian R Martineau
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-04       Impact factor: 11.205

10.  Neutrophil-mediated innate immune resistance to mycobacteria.

Authors:  Adrian R Martineau; Sandra M Newton; Katalin A Wilkinson; Beate Kampmann; Bridget M Hall; Niga Nawroly; Geoffrey E Packe; Robert N Davidson; Christopher J Griffiths; Robert J Wilkinson
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.